Advertisement

Opioid Prescribing

Resource Center

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

FDA Alert
fda
FDA Alert
Second OTC Naloxone Nasal Spray Approved by FDA
09/28/2023

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved the second over-the-counter nasal spray with the goal of increasing access to products that can rapidly reverse the effects of opioid overdose.
09/28/2023
opioids
opioids
FDA Approves Sublingual Opioid Despite Controversy
11/05/2018
The FDA has approved the sublingual opioid sufentanil (Dsuvia) fo
11/05/2018
Opioid addiction
Opioid addiction
FDA Advisers Back Non-Opioid Drug for Opioid Withdrawal
03/29/2018
The FDA’s Psychopharmacologic Drugs Advisory Committee recently reviewed and voted on whether to recommend lofexidine, a non-opioid drug, for the management of opioid withdrawal.
03/29/2018
opioids
opioids
Opioid Pulled From Market Following FDA Request
07/07/2017
Following an FDA-issued withdrawal request, an abuse-deterrent opioid will be removed from the market.
07/07/2017
opioids
opioids
Abuse-Deterrent Opioid Receives FDA Approval
04/26/2017
The first immediate-release opioid to receive abuse-deterrent labeling was recently approved by the FDA.
04/26/2017
Medication Prescribing
Medication Prescribing
FDA Issues Strong Warnings Against Combining Opioids and Benzodiazepine
09/01/2016
The FDA is requiring boxed warnings for opioid analgesics and prescription opioid cough products related to combined use of certain opioids with benzodiazepines.
09/01/2016
Treatment
Treatment
FDA Releases Final Guidance On Abuse-Deterrent Opioids
04/02/2015
The FDA has released its finalized industry guidance for the development of abuse-deterring opioid drugs.
04/02/2015